Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- Roche's first FDA-approved tumour-agnostic medicine
- Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
- Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
- Lilly, Evidation Health and Apple study shows personal digital devices may help in the identification of mild cognitive impairment and mild Alzheimer's disease dementia
- Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Research & Development
- Drug accelerates blood system's recovery after chemotherapy, radiation
- New drug shows encouraging survival in pancreatic cancer
- Ancient natural history of antibiotic production and resistance revealed
- Eating more plant-based foods may be linked to better heart health
- Rye is healthy, thanks to an interplay of microbes
- Closing the door: breaking new ground related to a potential anticancer drug target
- Leading oncologists and nutritionists pinpoint areas to catalyze nutrition-based cancer prevention
Conferences & Events
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
- Optima to host post-conference workshop at Lyophilization USA
- The need for a blueprint emergency plan to avoid a HPAPI crisis
- Ophthalmic Drugs Conference 2019
- Lyophilization USA Conference 2019
Regulatory Affairs
- FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
- FDA approves first therapy for rare joint tumor
- FDA approves first treatment for severe hypoglycemia that can be administered without an injection
- FDA approves first generics of Lyrica
- FDA approves new treatment for refractory multiple myeloma